j & j eats itself, page-4

TL have you just found the answer for the delay of the announcement with the second largest mass market player.

If your theory is right and J+J having offloaded Janssen Pharmaceuticals (owner of Retin-A Micro for acne, Ertaczo for athlete’s foot and Renova, another acne treatment) as part of its ongoing efforts to restructure itself after a pretty ordinary time of it of late including 25 product recalls, is now to focus on lower risk (aka less prescription based) revenues which subsequently shifts focus to TPM - you may have just found the answer for the delay in the POH's announcement of the mass market player if this article has anything to do with it -

http://www.ftc.gov/os/caselist/1110216/111209valeantjjagree.pdf

Essentially the Janssen sale is being delayed by the federal trade commission. POH may just be under orders to hold off until the dust has settled before J+J roll with a new non-prescription based product.